JY BioMed and YC Biotech Submit Parkinson’s Disease Regenerative Medicine Trial Proposal to TMU Joint IRB

April 2025 — Taipei

JY BioMed Co., Ltd. and YC Biotech Co., Ltd. are pleased to announce the formal submission of a regenerative medicine clinical research proposal for Parkinson’s disease to the Joint Institutional Review Board (IRB) of Taipei Medical University and its affiliated hospitals.

This investigator-initiated clinical study will explore the application of mesenchymal stem cell (MSC)-based therapy in patients with Parkinson’s disease, a progressive neurodegenerative disorder with limited therapeutic options. The proposed study represents a significant step forward in the clinical translation of regenerative strategies for neurodegenerative diseases in Taiwan.

Under this collaboration, JY BioMed will provide the core cell therapy platform and retains ownership of the associated technology and intellectual property. JY BioMed will also lead the scientific direction and strategic oversight of the program. YC Biotech will support clinical execution, including protocol design, regulatory dossier preparation, and coordination of clinical site operations. All activities will be conducted in accordance with Good Clinical Practice (GCP) guidelines and applicable regulatory standards.

The joint effort underscores both companies’ commitment to advancing the frontiers of regenerative medicine and addressing unmet medical needs in neurodegenerative disorders. Continued updates regarding this program and other pipeline developments will be provided through JY BioMed’s official website and communication channels.

About JY BioMed

JY BioMed is a biotechnology company focused on the development of innovative cell and exosome-based therapeutics for oncology, immunology, and regenerative medicine. The company is committed to rigorous science, global regulatory alignment, and responsible innovation.

Regulatory Disclaimer The investigational therapy described herein is currently under preclinical and early-stage regulatory evaluation. It has not been approved for clinical or commercial use by any regulatory authority.